[go: up one dir, main page]

WO2024030535A3 - Peripherally restricted gaba positive allosteric modulators for the treatment of irritable bowel syndrome and other ailments of the peripheral nervous system - Google Patents

Peripherally restricted gaba positive allosteric modulators for the treatment of irritable bowel syndrome and other ailments of the peripheral nervous system Download PDF

Info

Publication number
WO2024030535A3
WO2024030535A3 PCT/US2023/029383 US2023029383W WO2024030535A3 WO 2024030535 A3 WO2024030535 A3 WO 2024030535A3 US 2023029383 W US2023029383 W US 2023029383W WO 2024030535 A3 WO2024030535 A3 WO 2024030535A3
Authority
WO
WIPO (PCT)
Prior art keywords
positive allosteric
allosteric modulators
treatment
nervous system
peripheral nervous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2023/029383
Other languages
French (fr)
Other versions
WO2024030535A2 (en
Inventor
James C. Barrow
Ingrid Buchler
Yifang Huang
Michael Poslusney
Pankaj Jay Pasricha
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Lieber Institute Inc
Original Assignee
Johns Hopkins University
Lieber Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University, Lieber Institute Inc filed Critical Johns Hopkins University
Priority to EP23850739.6A priority Critical patent/EP4565225A2/en
Publication of WO2024030535A2 publication Critical patent/WO2024030535A2/en
Publication of WO2024030535A3 publication Critical patent/WO2024030535A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt thereof, or an N-oxide thereof), which are positive allosteric modulators of one or more GABA-A receptors, e.g., which are peripherally restricted, positive allosteric modulators of one or more GABA-A receptors; e.g., which are positive allosteric modulators of one or more GABA-A receptors and which selectively target the peripheral nervous system and organs of the body, and which do not substantially pass through the blood-brain barrier. Said compounds are useful e.g., for the treatment of systemic diseases of the body, e.g., diseases in which modulation of one or more peripherally restricted GABA-A receptors is beneficial.
PCT/US2023/029383 2022-08-03 2023-08-03 Peripherally restricted gaba positive allosteric modulators for the treatment of irritable bowel syndrome and other ailments of the peripheral nervous system Ceased WO2024030535A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP23850739.6A EP4565225A2 (en) 2022-08-03 2023-08-03 Peripherally restricted gaba positive allosteric modulators for the treatment of irritable bowel syndrome and other ailments of the peripheral nervous system

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263370329P 2022-08-03 2022-08-03
US63/370,329 2022-08-03

Publications (2)

Publication Number Publication Date
WO2024030535A2 WO2024030535A2 (en) 2024-02-08
WO2024030535A3 true WO2024030535A3 (en) 2024-04-11

Family

ID=89849731

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2023/029383 Ceased WO2024030535A2 (en) 2022-08-03 2023-08-03 Peripherally restricted gaba positive allosteric modulators for the treatment of irritable bowel syndrome and other ailments of the peripheral nervous system

Country Status (2)

Country Link
EP (1) EP4565225A2 (en)
WO (1) WO2024030535A2 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3943145A (en) * 1972-12-29 1976-03-09 Ciba-Geigy Corporation 6-Phenyl-4H-v-triazolo[1,5-a][1,4]benzodiazepines
US20100261711A1 (en) * 2009-03-20 2010-10-14 Wisys Technology Foundation Selective anticonvulsant agents and their uses
US20120295892A1 (en) * 2011-04-28 2012-11-22 Uwm Research Foundation, Inc. Gabaergic receptor subtype selective ligands and their uses
US8835424B2 (en) * 2002-03-28 2014-09-16 Wisconsin Alumni Research Foundation Selective agents for pain suppression

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3943145A (en) * 1972-12-29 1976-03-09 Ciba-Geigy Corporation 6-Phenyl-4H-v-triazolo[1,5-a][1,4]benzodiazepines
US8835424B2 (en) * 2002-03-28 2014-09-16 Wisconsin Alumni Research Foundation Selective agents for pain suppression
US20100261711A1 (en) * 2009-03-20 2010-10-14 Wisys Technology Foundation Selective anticonvulsant agents and their uses
US20120295892A1 (en) * 2011-04-28 2012-11-22 Uwm Research Foundation, Inc. Gabaergic receptor subtype selective ligands and their uses

Also Published As

Publication number Publication date
WO2024030535A2 (en) 2024-02-08
EP4565225A2 (en) 2025-06-11

Similar Documents

Publication Publication Date Title
EP4424372A3 (en) Compounds and methods for treatment of viral infections
EP4275702A3 (en) Cd70 combination therapy
WO2005025511A3 (en) Potassium channel mediated delivery of agents through the blood-brain barrier
BR0316753A (en) Treatment method for sexual dysfunction
EP2295402A3 (en) Antibacterial agents
EP4537828A3 (en) Phospholipid compounds and uses thereof
NO20091296L (en) Procedure for the treatment of thrombolytic agents
MX2023001071A (en) Treatment of migraine.
WO2004073640A3 (en) Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy
CA2383785A1 (en) Methods of using rapid-onset selective serotonin reuptake inhibitors for treating sexual dysfunction
WO2020190890A8 (en) Nicorandil derivatives
WO2004039322A3 (en) Novel combination therapy for schizophrenia focused on improved cognition: 5-ht-2a/d2 blockade with adjunctive blockade of prefrontal da reuptake
MX2024003952A (en) Combination comprising atogepant for treating migraine.
MX2022009197A (en) Methods of treatment for alpha-1 antitrypsin deficiency.
PH12020551772A1 (en) Oxo-substituted compound
WO2025038785A9 (en) Sos1 protein degraders, pharmaceutical compositions, and therapeutic applications
WO2024030535A3 (en) Peripherally restricted gaba positive allosteric modulators for the treatment of irritable bowel syndrome and other ailments of the peripheral nervous system
MX2025008009A (en) Modulators of bcl6 proteolysis and associated methods of use
WO2006081431A3 (en) Compounds for treating inflammatory and demyelinating diseases
WO2022106902A3 (en) Benzenesulfonamide derivatives and uses thereof
WO2024030543A3 (en) Peripherally restricted gaba positive allosteric modulators for the treatment of irritable bowel syndrome and other ailments of the peripheral nervous system
RU2006107552A (en) ALPHA-2-DELTA LIGAND COMBINATIONS AND SEROTONIN / NORADRENALINE REVERSION INHIBITORS
BRPI0515954A (en) pharmaceutically acceptable compound and salts thereof and individual enantiomers and diastereomers thereof, pharmaceutical composition, and methods for inhibiting the glyt1 glycine transporter in a mammal for the manufacture of a medicament for inhibiting the glyt1 glycine transporter in a mammal to to treat a neurological and psychiatric disorders associated with glycergic or glutamatergic neurotransmission dysfunction in a mammalian patient and to treat schizophrenia in a mammalian patient
PH12022550983A1 (en) Novel substituted condensed ring compound
WO2007092436A3 (en) Compounds for treating inflammatory disorders, demyelinating disorders and cancers

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23850739

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2023850739

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2023850739

Country of ref document: EP

Effective date: 20250303

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23850739

Country of ref document: EP

Kind code of ref document: A2

WWP Wipo information: published in national office

Ref document number: 2023850739

Country of ref document: EP